Ocular Therapeutix, Inc.
OCUL
$11.87
-$0.43-3.50%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -54.91% | 1.23% | -65.60% | -6,972.29% | -111.67% |
Total Depreciation and Amortization | 7.32% | 6.63% | -0.73% | 7.75% | 46.63% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -26.13% | -70.10% | -42.16% | 101.30% | 228.31% |
Change in Net Operating Assets | -82.36% | 142.52% | 113.09% | -119.46% | 168.34% |
Cash from Operations | -122.72% | -31.82% | -75.60% | -372.83% | -23.55% |
Capital Expenditure | -67.79% | -658.04% | 55.99% | 65.64% | 62.71% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -50.27% | -658.04% | 55.99% | 65.64% | 62.71% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 4,353.83% | -98.70% | -95.83% | 442.60% | -77.23% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 4,353.83% | -98.70% | -95.83% | -91.96% | -77.23% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 277.54% | -114.78% | -141.19% | -173.89% | -87.99% |